JP2009544703A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544703A5
JP2009544703A5 JP2009521795A JP2009521795A JP2009544703A5 JP 2009544703 A5 JP2009544703 A5 JP 2009544703A5 JP 2009521795 A JP2009521795 A JP 2009521795A JP 2009521795 A JP2009521795 A JP 2009521795A JP 2009544703 A5 JP2009544703 A5 JP 2009544703A5
Authority
JP
Japan
Prior art keywords
seq
amino acids
trka
item
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544703A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/016589 external-priority patent/WO2008013782A2/en
Publication of JP2009544703A publication Critical patent/JP2009544703A/ja
Publication of JP2009544703A5 publication Critical patent/JP2009544703A5/ja
Pending legal-status Critical Current

Links

JP2009521795A 2006-07-24 2007-07-24 Sp35またはTrkAアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法 Pending JP2009544703A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83258606P 2006-07-24 2006-07-24
US83665206P 2006-08-10 2006-08-10
PCT/US2007/016589 WO2008013782A2 (en) 2006-07-24 2007-07-24 Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists

Publications (2)

Publication Number Publication Date
JP2009544703A JP2009544703A (ja) 2009-12-17
JP2009544703A5 true JP2009544703A5 (cg-RX-API-DMAC7.html) 2010-09-09

Family

ID=38982011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521795A Pending JP2009544703A (ja) 2006-07-24 2007-07-24 Sp35またはTrkAアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法

Country Status (4)

Country Link
US (1) US8642040B2 (cg-RX-API-DMAC7.html)
EP (1) EP2068866A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009544703A (cg-RX-API-DMAC7.html)
WO (1) WO2008013782A2 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1569696T3 (da) * 2002-11-21 2010-11-15 Bayhill Therapeutics Inc Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
EP1959979A4 (en) * 2005-11-04 2010-01-27 Biogen Idec Inc PROCESS FOR PROMOTING AXON GROWTH AND SURVIVAL OF DOPAMINERGIC NEURONS
US20090175872A1 (en) * 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
EP2068866A4 (en) 2006-07-24 2010-04-07 Biogen Idec Inc METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
US20110118340A1 (en) * 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
EP2580238A1 (en) * 2010-06-09 2013-04-17 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012149024A2 (en) 2011-04-28 2012-11-01 Mayo Foundation For Medical Education And Research Dna aptamers for promoting remyelination
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
US9699433B2 (en) 2013-01-24 2017-07-04 Yuchen Zhou Method and apparatus to produce re-focusable vision with detecting re-focusing event from human eye
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
KR101878925B1 (ko) * 2017-01-25 2018-07-16 한국과학기술연구원 희소돌기아교세포 분화용 조성물 및 이를 이용한 희소돌기아교세포 분화방법
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
WO2020072456A1 (en) * 2018-10-02 2020-04-09 Case Western Reserve University Compounds for treating myelin related disorders
WO2020118218A1 (en) 2018-12-06 2020-06-11 Mayo Foundation For Medical Education And Research Short dna aptamers and methods for promoting remyelination
CN113481204B (zh) * 2021-07-02 2022-08-12 湖南赛奥维生物技术有限公司 一种蛋白的核酸适配体、其衍生物及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219837A (en) 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
DK0790246T3 (da) 1994-10-25 2002-03-18 Toyama Chemical Co Ltd Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
JP2000501416A (ja) * 1996-04-26 2000-02-08 ユニバーシティー オブ オタワ ニューロン病を治療し予防するための、治療法および薬物のスクリーニング法
WO1997040847A1 (en) 1996-04-26 1997-11-06 University Of Ottawa Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
AU721942B2 (en) 1996-06-25 2000-07-20 Cephalon, Inc. Use of K-252A derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
FR2776661B1 (fr) * 1998-03-26 2002-04-05 Centre Nat Rech Scient Polypeptide immunoreactif du recepteur trka du ngf et utilisations
US7282482B2 (en) 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HUP0203863A3 (en) 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
WO2001052843A1 (en) 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
BR0206985A (pt) 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
ATE469913T1 (de) 2002-08-10 2010-06-15 Univ Yale Antagonisten des nogo-rezeptors
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20040186044A1 (en) * 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
JP2007501612A (ja) 2003-08-07 2007-02-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド Nogo受容体アンタゴニスト
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
CA2609077A1 (en) 2005-05-16 2006-12-28 Mcgill University Lgi, lingo and p75ntr family members: novel modulators of neuronal growth
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
US20090175846A1 (en) 2005-10-27 2009-07-09 Biogen Idec Ma Inc Oligodendrocyte-Myelin Glycoprotein Compositions and Methods of Use Thereof
EP1959979A4 (en) 2005-11-04 2010-01-27 Biogen Idec Inc PROCESS FOR PROMOTING AXON GROWTH AND SURVIVAL OF DOPAMINERGIC NEURONS
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
CN101405297A (zh) 2006-02-03 2009-04-08 惠氏公司 Lingo-1结构
WO2007098283A2 (en) 2006-02-27 2007-08-30 Biogen Idec Ma Inc. Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders
EP2068866A4 (en) 2006-07-24 2010-04-07 Biogen Idec Inc METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS
CN103351437A (zh) 2006-11-17 2013-10-16 诺瓦提斯公司 Lingo结合分子及其制药用途
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CA2701189C (en) 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
ES2464459T3 (es) * 2008-06-25 2014-06-02 H. Lundbeck A/S Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof

Similar Documents

Publication Publication Date Title
JP2011500566A5 (cg-RX-API-DMAC7.html)
JP2010518007A5 (cg-RX-API-DMAC7.html)
US6531295B1 (en) Synthetic constructs encoding syndecan
EP3169784B1 (en) Rnai compositions to treat apoc3-related diseases
US6844168B1 (en) Compositions comprising polynucleotides encoding human fibroblast growth factor receptor and uses thereof
Thomas et al. Molecular cloning of the fMet-Leu-Phe receptor from neutrophils
US7205387B2 (en) Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
AU2020280438B2 (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US20090215814A1 (en) Method of inhibiting neurotrophin-receptor binding
CA3225542A1 (en) Oligonucleotide conjugates targeted to the transferrin receptor
EP3101029A1 (en) Variants of activin iib receptor polypeptides and uses thereof
US20090305951A1 (en) Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival cells
NZ568705A (en) Methods for promoting neurite outgrowth and survival of dopaminergic neurons
EP4602164A2 (en) Small interfering rna targeting c3 and uses thereof
Lappi Tumor targeting through fibroblast growth factor receptors
Wilkemeyer et al. Alcohol inhibition of cell adhesion in BMP‐treated NG108‐15 cells
Nakayama et al. α4 is a major acetylcholine binding subunit of cholinergic ligand affinity-purified nicotinic acetylcholine receptor from rat brains
US20080254023A1 (en) Treating Gliosis, Glial Scarring, Inflammation or Inhibition of Axonal Growth in the Nervous System by Modulating Eph Receptor
US20090130701A1 (en) Novel sequence variants of multi-drug resistance genes, mdr1 and mrp1, and recombinant cells expressing mrp1 and mdr1 for assessment of drug penetration and disposition
Karle et al. Antisense oligonucleotide to GABAA receptor γ2 subunit induces loss of neurones in rat hippocampus
US20050069537A1 (en) Survical promoting ncam binding and ncam ligand binding compounds
Ko et al. Cyclic AMP regulates basement membrane heparan sulfate proteoglycan, perlecan, metabolism in rat glomerular epithelial cells
US6699968B1 (en) Construction and use of synthetic constructs encoding syndecan
US6423827B1 (en) Limbic system-associated membrane protein
US20070116702A1 (en) Survival promoting NCAM binding and MCAM ligand binding compounds